Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
about
Colony-stimulating factors for chemotherapy-induced febrile neutropeniaAntibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapyGranulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphomaProphylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapyG-CSF and GM-CSF in NeutropeniaThe impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trialsPredicting neutropenia risk in patients with cancer using electronic data.Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702Filgrastim improves survival in lethally irradiated nonhuman primatesProphylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisTreatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades.Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice.Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.Fluoroquinolone resistance in bacteremic and low risk febrile neutropenic patients with cancer.The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort studyEmerging agents for the prevention of treatment induced neutropenia in adult cancer patients.The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthaseCanadian supportive care recommendations for the management of neutropenia in patients with cancer.Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric studyXM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.Prevention of febrile neutropenia: use of prophylactic antibiotics.Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.A nonhuman primate model of the hematopoietic acute radiation syndrome plus medical management.Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.Treatment options for esophageal squamous cell carcinoma.Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.Immunotherapy prospects in the treatment of lung cancer and mesothelioma.Immune Therapy.Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer.Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy.H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients.Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
P2860
Q24193040-C67EA8EB-2426-4843-BD92-FB782780F837Q24203869-EEB76FBF-EBAB-4E97-8C3F-CDF501678807Q24240753-82810EDE-117C-4EBC-8AA1-3790E34342F2Q24241680-B5B3D8F7-F0B3-457F-961E-335BF8BE7038Q26800954-68D1DA59-A847-4943-8CD4-6EF24417F604Q27008080-393F46C3-EE82-4CB8-A7CF-A9FB275FEFE6Q31131362-6415D208-A079-4415-9A08-10DF257FF521Q33375619-02C1DB31-1345-4CDA-8363-31BDAAD761D6Q33390547-A260B701-3C2B-47B0-8B6E-020CA8DDD97FQ33756369-5A00C573-A0ED-4BCC-AC23-2A5D076A2339Q34029496-A8C7B46E-102C-4D4D-8831-501BD6B68BFFQ34374754-E95AADA5-189A-41D1-933F-E8CDEB1C02EBQ34553998-19593EC4-D910-42F0-BA0F-6407B0FACA9EQ34620664-5614ED43-07CF-431C-B776-769D5D6AB42EQ34670717-EC019461-7E5D-4FAE-93D6-D4F8A3AAAF3BQ35078855-C47CC339-A63F-4F26-8743-547A90980B2FQ35916166-40CD266C-D7CD-4AD4-8221-BE32C4817616Q36007020-1821EB54-EA6D-4C2C-9AE2-15771E237F26Q36269159-3200A292-51E1-44EE-B143-316AAC4B1EF3Q36485208-BB493B31-7A62-4EC2-934A-7B46698B7492Q36677460-C453D726-C41B-46CA-A213-C20419D05992Q36723952-89172313-6A39-41FF-9167-1E4BDEB86925Q37067591-730DAC2C-911A-44EE-9346-ABA1E2F1D493Q37182159-862BDB1E-3DF3-4061-A7BB-42DB61BCCC5EQ37363337-207AB9E8-B307-4DD5-939E-B91A411BE4B1Q37373201-4CCAFBB0-BE22-445A-8CEC-BC3B5CE7E06EQ37424451-4396BC77-4665-4403-8F8A-CBA6FE71073CQ37831314-0999B8C8-1411-41A7-850D-6C5AC79213FDQ37931905-1EBA02C7-FB42-4D2D-804F-2EB761934DFEQ38006021-750909D8-A42E-497E-8693-7B835A8D9B73Q38107007-BFA54A23-460D-4E68-BCA6-55EAD1ABFC56Q38225700-6512092D-0FB4-4B20-ACFB-3A15762DF5A3Q38256944-6899AE56-8DAB-4CDF-86DC-70D404092152Q38390104-BCEBFA01-4183-44F2-B37E-576E896BCBF0Q38669273-C1DE6AFA-0AF0-4C3F-B48D-E649D275719CQ39074316-A5C8BBCD-0C00-491B-8359-573A222BD7D6Q40307046-DBBE9B04-DC06-484E-97D3-231A9DA1EC39Q40316147-42CEEE66-53C5-4D84-9B19-8DEB0D2FC883Q40382932-72B0DA6E-C88A-4BD8-803A-0947ACC1ACDBQ40796585-4F5FCB3F-4F4B-4F29-A95A-0963EF562A1C
P2860
Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Prevention of chemotherapy-ind ...... ch Randomized Phase III Study.
@ast
Prevention of chemotherapy-ind ...... ch Randomized Phase III Study.
@en
Prevention of chemotherapy-ind ...... ch Randomized Phase III Study.
@nl
type
label
Prevention of chemotherapy-ind ...... ch Randomized Phase III Study.
@ast
Prevention of chemotherapy-ind ...... ch Randomized Phase III Study.
@en
Prevention of chemotherapy-ind ...... ch Randomized Phase III Study.
@nl
prefLabel
Prevention of chemotherapy-ind ...... ch Randomized Phase III Study.
@ast
Prevention of chemotherapy-ind ...... ch Randomized Phase III Study.
@en
Prevention of chemotherapy-ind ...... ch Randomized Phase III Study.
@nl
P2093
P921
P356
P1476
Prevention of chemotherapy-ind ...... ch Randomized Phase III Study.
@en
P2093
Arien Termeer
Bonne Biesma
Cornelis A Hensing
Eddy M Adang
Frank A Wilschut
Geeben P Bootsma
Hans J Smit
Janine Akkermans
Johanna N Timmer-Bonte
Samia A Cheragwandi
P304
P356
10.1200/JCO.2004.00.7955
P407
P577
2005-11-01T00:00:00Z